Over one million individuals are identified with pancreatic cysts every year. IPMNs and MCNs, are pre-cursors to pancreatic cancer, and offer the opportunity for the early detection, or even prevention, of pancreatic cancer. In contrast, serous cystadenomas or pseudocysts, are benign. Currently tools are inadequate to fully delineate these lesions prior to surgical resection, with up to 68% of the operations performed on patients with a pancreatic cyst ultimately found to be unnecessary. Guidelines recommend lifelong surveillance for IPMNs, however this is based on the lowest level of scientific evidence. Furthermore, no data exists on the molecular progression of IPMNs and MCNs in situ. We developed a Comprehensive Cyst (CompCyst) EUS companion test which combines clinical, radiological, genetic and protein marker data. In an initial evaluation of 862 surgically resected pancreatic cysts, the CompCyst test had a superior performance for identifying cysts which required surgery, needed surveillance, or were benign, compared with the current routine evaluation.
The Aims of the proposed project are to:
Aim 1 : Evaluate the genetic and clinical natural history of pancreatic cysts in a prospective international study.
Aim 2 : Evaluation and optimization of approaches for the management of pancreatic cysts.
Aim 3 : Develop a Second-Generation CompCyst test (CompCyst2). The overarching goal of Project 3 is to develop a clinically relevant tool which will be incorporated into clinical practice and will improve outcomes for patients with pancreatic cysts, specifically avoiding unnecessary surveillance or surgical resection.
Pancreatic cysts are common and certain types can be precursors to invasive pancreatic cancer. Because of the risk of complications and death associated with either the under or over treatment of pancreatic cysts, better diagnostic methods for distinguishing pancreatic cyst type are required. The goal of this translational project is to develop a test that integrates clinical, imaging, molecular and protein data, to improve the management of pancreatic cysts, which will ultimately be used in clinical practice.
Showing the most recent 10 out of 883 publications